Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 16, 2025 08:30 ET | Source: Femasys Inc.

Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment

FemaSeed® patent application provides additional coverage for Femasys’ therapeutic option for women seeking infertility solution ATLANTA, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq:...
December 03, 2024 09:00 ET | Source: Femasys Inc.

Femasys Announces Partnership with HRC Fertility, Esteemed Conglomerate Provider of Fertility Services in Western U.S., to Offer FemaSeed

ATLANTA, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of...
November 26, 2024 08:30 ET | Source: Femasys Inc.

Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility Treatment

ATLANTA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of...
November 12, 2024 08:30 ET | Source: Femasys Inc.

Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update

ATLANTA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of...
November 07, 2024 08:30 ET | Source: Femasys Inc.

Femasys to Exhibit at the Annual AAGL 2024 Global Conference

ATLANTA, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of...
November 01, 2024 08:30 ET | Source: Femasys Inc.

Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control

ATLANTA, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of...
October 30, 2024 09:00 ET | Source: Femasys Inc.

Femasys Announces Partnership with Boston IVF, Prominent Network of Fertility Centers, to Offer FemaSeed

ATLANTA, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of...
October 10, 2024 08:30 ET | Source: Femasys Inc.

Femasys to Exhibit at ASRM 2024 and Participate in the Congress’ KEEPR Education Program

ATLANTA, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of...
October 08, 2024 08:30 ET | Source: Femasys Inc.

Femasys to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

ATLANTA, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of...
October 02, 2024 08:30 ET | Source: Femasys Inc.

Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments

ATLANTA, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of...